---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-23-000108"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:26:06.682391+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q3 revenue $42.6M (+15% YoY); net loss widens to $62M; updates guidance

## Summary
- Total revenue $42.6M (+15% YoY); software revenue $28.9M (+17%); drug discovery $13.7M (+11%).
- Net loss $62.0M vs $39.9M in Q3 2022; operating expenses rose 26% to $79.8M.
- Updated FY2023 guidance: software revenue growth 15-18%; drug discovery $50-70M; cash from ops expected higher.
- Pipeline: SGR-1505 healthy volunteer data due Q4; SGR-2921 Phase 1 started; PRMT5-MTA program disclosed.
- Bristol Myers Squibb returned rights to two oncology programs; company maintains ~$503M cash.

## SEC filing metadata
- accession: 0001490978-23-000108
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000108/0001490978-23-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000108/sdgr-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-23-000108
- JSON: https://secwatch.observer/filing/0001490978-23-000108.json
- Plain text: https://secwatch.observer/filing/0001490978-23-000108.txt

## Key facts
- Earnings Releases
  Schrodinger, Inc. reported the third quarter ended September 30, 2023 results: revenue $42.6 million, net income $71.4 million. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $42.6 million
  - Net income: $71.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Schrödinger Reports Third Quarter 2023 Financial Results Delivers Third Quarter Total Revenue of $42.6 Million; Maintains Full-Year 2023 Revenue Guidance Continued Progress for SGR-1505, Healthy Volunteer Data Expected in Fourth Quarter of 2023 Phase 1 Study Initiated for SGR-2921;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000108/0001490978-23-000108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.